Our Pipeline

SynuSight is committed to delivering FIC and BIC diagnostic and therapeutic solutions for patients with neurodegenerative diseases.

Candidate Indication Early Discovery Pre-clinical IND Phase I Phase II Phase III
SST001/18F-FD4
α-Syn PET tracer
Partnering with The Michael J. Fox Foundation (MJFF)		 PD, MSA, DLB
SST002
PET tracer		 Undisclosed
SSA001
Novel Biomarker		 Undisclosed
SSA002
Novel Biomarker		 Undisclosed
Candidate
SST001/FD4
α-Syn PET tracer
Partnering with The Michael J. Fox Foundation (MJFF)
IndicationPD, MSA, DLB
Early Discovery Pre-clinical IND Phase I Phase II Phase III
Candidate
SST002
PET tracer
IndicationUndisclosed
Early Discovery Pre-clinical IND Phase I Phase II Phase III
Candidate
SSA001
Novel Biomarker
IndicationUndisclosed
Early Discovery Pre-clinical IND Phase I Phase II Phase III
Candidate
SSA002
Novel Biomarker
IndicationUndisclosed
Early Discovery Pre-clinical IND Phase I Phase II Phase III